Caesar Akbar, Jakarta – The Food and Drugs Monitoring Agency (BPOM) cautioned stakeholders, including pharmaceutical firms that produce Ivermectin, to stop promoting the medicine as a therapeutic drug for Covid-19 as the agency has not yet authorized the use of the drug.
"Ivermectin is a potent drug and the expanded access program (EAP) is not a distribution permit approval, which is why we encourage pharmaceutical industry producing the drug and anyone to not promote the drug," the BPOM website wrote on Wednesday, July 21.
This drug, BPOM stated, is classified as a drug that allegedly has potency to fight against Covid-19. But it needs further evidence through clinical trials which is being held by the Health Ministry's policy review agency.
The wider use of the drug by the Health Ministry and healthcare facilities must get the approval from the BPOM that will later be included in the EAP scheme. A drug is acknowledged as an EAP drug when the health governing body deems it necessary to be used under an emergency situation.
BPOM previously issued a technical guideline of the use of the drugs under the Expanded Access Program.